Abstract 72P
Background
Group 3 Medulloblastoma (MB) is a subgroup of MB with poor prognosis and high chances of recurrence. The highly aggressive nature of this paediatric brain tumor necessitates targeted therapeutic approaches to improve patient outcomes. Phosphoenolpyruvate carboxykinase plays a crucial role in gluconeogenesis by catalyzing the conversion of oxaloacetate to phosphoenolpyruvate. PCK2 is the mitochondrial counterpart of this enzyme, helping in replenishment of various metabolic intermediates and hence acting as a pivotal protein between pyruvate metabolism, TCA cycle and gluconeogenesis. Recent proteomic studies on Medulloblastoma (MB) suggest extensive metabolic rewiring in Group 3 MB.
Methods
Analysis of publicly available omics data on Medulloblastoma was performed to identify the expression levels of proteins related to key metabolic pathways like Krebs cycle, pyruvate metabolism and glucose metabolism including PCK2. Key proteins belonging to these pathways were analysed in FFPE tissues from MB patients and compared with other subgroups using multiple reaction monitoring. PCK2 was knocked down in Group 3 cell lines using shRNA and evaluated for effects on proliferation and survival using culture based in vitro assays. High resolution label free proteomic analysis was performed to ascertain the effects of PCK2 knockdown.
Results
Data mining and repository data analysis found dysregulation of key proteins and metabolites. Key proteins involved in energy metabolism including PCK2 showed upregulation even at the transcriptomic level. Proteomic analysis on few FFPE samples could validate these findings. shRNA based PCK2 knockdown resulted in lowering the proliferation rates of Group 3 cells and significant changes in their proteomes.
Conclusions
The overexpression of PCK2 is involved in the aggressiveness of Group 3 MB and can be a possible target for this subset of medulloblastoma patients.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
IIT Bombay.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
94P - Harnessing circulating tumor DNA in bronchoalveolar lavage fluid for precise molecular diagnosis of NSCLC
Presenter: Frank Borm
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Automatic data processing to identify EGFR mutations in pathology reports of patients with non-small cell lung cancer (NSCLC)
Presenter: Betzabel Cajiao Garcia
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in endometrial cancer (EC) patients
Presenter: Simona Duranti
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Prospects of liquid biopsy in determining prognosis in children with HGG and DIPG
Presenter: Olga Regentova
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Liquid biopsy in NSCLC: A promising tool to predict immunotherapy response
Presenter: Ana Fernández
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Comprehensive genomic sequencing as an ancillary diagnostic tool for pathologists
Presenter: Dan Miller
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Standard serum biomarkers to help predict a cancer diagnosis in patients with non-specific symptoms: Data from Guy´s rapid diagnostic clinic
Presenter: Maria Monroy Iglesias
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Patient-derived organoids to optimize CDK4/6 inhibitor-based treatment selection in early breast cancer
Presenter: Carla Alves
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - MicroRNAs in urine and saliva as non-invasive biomarkers of minimal residual disease in pediatric acute lymphoblastic leukemia
Presenter: Alejandra Pando-Caciano
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - MSI detection by NGS using tumor samples and liquid biopsy for patients with solid tumors: A single institution experience
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract